Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Horizon Kinetics is Bullish on Charles River Laboratories (CRL) Stock?

Horizon Kinetics LLC, a New York-based investment advisory firm founded in 1994, released its Q1 2020 Commentary – a copy of which is available for download here. It has over 70 employees and is led by Murray Stahl. Its investment strategy is long-term and contrarian oriented, and the fund usually holds a concentrated portfolio with original stock picks.

In the said letter, Horizon Kinetics highlighted a few stocks and Charles River Laboratories International Inc. (NYSE:CRL) is one of them. Charles River Laboratories engages in a number of preclinical and clinical laboratory services for the medical device, pharmaceutical,  and biotechnology industries. Year-to-date, CRL stock lost 5.3% and on April 28th it had a closing price of $139.95. Its market cap is of $7.16 billion. Here is what Horizon Kinetics said:

“We lately added a small position in Charles River Laboratories. It is not a particularly cheap company; it trades at about 19x estimated earnings for this year. But it is a high-quality business. It provides a service that is much in demand by a very large population of well-funded entities, a service that is not easily replicable and is very value added. Its revenue growth, exclusive of acquisitions, is about 8% per year. The per-share earnings growth rate in the past 4 years has been over 12%.

Charles River Labs is a so-called contract research organization. It is the world’s largest provider of outsourced early-stage drug discovery, non-clinical development and safety assessment studies, including FDA-mandated testing for sterile biopharmaceutical products. This is not just for the pharmaceutical companies, but also for academic institutions and government agencies. The company serves customers that either have their own research capabilities but are operating at capacity and don’t wish to expand their fixed costs, or that can use the company’s specialized capabilities. No customer accounts for as much as 3% of revenues.

And behind all of this is that it takes up to $2 billion and a decade or longer – excluding the time and cost of exploring thousands of different molecules – to produce a single FDA approved drug. The COVID-19 pandemic cannot but help but engender continued efforts at microbial disease identification and treatment. The company’s manufacturing segment, which accounts for 18% of revenue, includes diagnostic products used to manufacture vaccines.”

In Q4 2019, the number of bullish hedge fund positions on CRL stock decreased by about 3% from the previous quarter (see the chart here).

Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.